We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MRI with Nanoparticles Detects Tiny Tumors

By Biotechdaily staff writers
Posted on 09 May 2005
Specifically designed nanoparticles can reveal very small tumors that are invisible by ordinary measures of detection, according to a new study.

Investigators have shown that tiny human melanoma tumors growing in mice--indistinguishable from the neighboring tissue by direct magnetic resonance imaging (MRI)--could be "lit up” and easily detected as quickly as 30 minutes after the mice were injected with the nanoparticles.

"One of the best advantages of the particles is that we designed them to detect tumors using the same MRI equipment that is in standard use for heart or brain scans,” remarked Gregory Lanza, M.D., Ph.D., associate professor of medicine at Washington University School of Medicine (St. More...
Louis, MO, USA), and senor author of the study.

The effectiveness of the technology will be assessed in clinical trials in approximately one and one-half years. The spherical nanoparticles are a few thousand times smaller than
the dot about a typewritten i; however, each can carry approximately 100,000 molecules of the metal used to provide contrast for the MR images. This creates a very high density of contrast agent, and when the particles bind to a certain region, that site glows brightly in MRI scans.

In this study, MRI captured tumors that were only a couple of millimeters wide. Tiny, quickly growing tumors cause growth of new blood vessels, which then feed the tumors, a process called angiogenesis. Nanoparticles are very useful since they are so adaptive, according to Dr. Lanza. "We can also make these particles so that they can be seen with nuclear imaging, CT [computed tomography] scanning, and ultrasound imaging,” said Dr. Lanza.

Utilizing nanoparticles, drug doses could be much small than those commonly used in chemotherapy, making the procedure potentially safer. The nanoparticles may also allow for more effective follow-up since clinicians could use them to decipher whether a tumor was still growing after chemotherapy or radiation therapy. The scientists believe the technology should work for most solid tumors, because all tumors must enlist new blood vessels to attain nutrients as they grow.

Melanoma has a horizontal stage, when it metastasizes across the skin surface, and a vertical stage, when goes deep into the body and grows rapidly. "With the nanoparticles, we believe we would be able to see the smallest melanoma tumors when they are just large enough to begin new blood vessel formation,” said Dr. Lanza. The researchers published their findings in the March 2005, issue of the journal Magnetic Resonance in Medicine.


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.